Edition:
India

Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

849.75INR
3:59pm IST
Change (% chg)

Rs13.00 (+1.55%)
Prev Close
Rs836.75
Open
Rs833.90
Day's High
Rs851.70
Day's Low
Rs826.00
Volume
2,434,628
Avg. Vol
2,701,904
52-wk High
Rs1,090.00
52-wk Low
Rs723.65

Chart for

About

Lupin Limited is a pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The Company offers products in the cardiovascular, diabetology, asthma, pediatrics, central... (more)

Overall

Beta: -0.05
Market Cap(Mil.): Rs469,414.59
Shares Outstanding(Mil.): 451.84
Dividend: 7.50
Yield (%): 0.72

Financials

  LUPN.NS Industry Sector
P/E (TTM): 23.14 30.93 32.76
EPS (TTM): 44.89 -- --
ROI: -- 15.07 14.61
ROE: -- 16.59 16.33

India's Lupin first-quarter profit misses estimate by wide margin

Drugmaker Lupin Ltd posted a bigger-than-expected fall in first-quarter profit on Wednesday, hurt by declining sales in the United States and Japan.

08 Aug 2018

UPDATE 1-India's Lupin Q1 profit misses estimate by wide margin

Aug 8 Drugmaker Lupin Ltd posted a bigger-than-expected fall in first-quarter profit on Wednesday, hurt by declining sales in the United States and Japan.

08 Aug 2018

India's Lupin quarterly profit falls 43 pct

Aug 8 Drugmaker Lupin Ltd posted a 43 percent fall in first-quarter profit on Wednesday, widely missing analysts' estimates.

08 Aug 2018

ICRA ratings for Indian debt instruments-Aug 3

Aug 3 Below are the ratings awarded by Investment Information Credit Rating Agency Ltd. (ICRA) for local debt instruments as of August 2, 2018. COMPANY INSTRUMENT RATING AMOUNT MOVEMENT (RS.MLN) ------ ---------- ------ ----- --------- SHORT TERM RATINAGS: ------------------- Aditya Birla Capital Ltd

03 Aug 2018

BUZZ-Weak Q1 expected for Cadila, Lupin; improving trends for Cipla, Sun - Credit Suisse

** April-June quarter should be weak for Cadila Healthcare Ltd and Lupin Ltd with sharp declines in U.S. sales q-o-q - Credit Suisse (CS)

09 Jul 2018

Lupin expects U.S. drug pricing pressure to ease in 2019

India's second-largest drugmaker Lupin Ltd said on Wednesday it expected pressure on drug prices in the United States, which has hit its profits, to ease this year as larger rivals reduce their exposure there.

15 May 2018

UPDATE 2-India's Lupin expects U.S. drug pricing pressure to ease in 2019

* U.S. sales fall 21.1 pct; India sales up 14 pct (Adds management comments from conference call)

15 May 2018

India's Lupin posts surprise Q4 loss on one-time charge

May 15 Lupin Ltd, India's second-largest drugmaker by revenue, reported a surprise loss in its fiscal fourth quarter on Tuesday, due to a one-time charge.

15 May 2018

BRIEF-India's Lupin Posts March Quarter Consol Net Loss

* MARCH QUARTER CONSOL NET LOSS 7.84 BILLION RUPEES VERSUS PROFIT OF 3.80 BILLION RUPEES LAST YEAR

15 May 2018

BRIEF-Lupin Launches Corcal Bone And Beauty Supplement

* LAUNCHES CORCAL BONE AND BEAUTY SUPPLEMENT Source text: http://bit.ly/2I8514t Further company coverage:

10 May 2018

Earnings vs. Estimates